Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Microneedling improves the appearance and feel of post-burn scars.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.

This study found that persistent chemotherapy-induced alopecia is often more severe and diffuse than alopecia from endocrine therapy, with both conditions negatively impacting patients' emotional wellbeing, and moderate to significant improvement was observed with dermatologic therapy.

This case report described cosmetically significant hair regrowth in a 39-year-old woman with permanent chemotherapy-induced alopecia after continuous oral minoxidil use.

This case report describes a patient with permanent chemotherapy-induced alopecia who experienced full hair regrowth after treatment with low-dose oral minoxidil.

This article highlights that permanent chemotherapy-induced alopecia can occur and is more commonly associated with taxane therapy, advising awareness among patients and clinicians.

This study reports that scalp cooling therapies and minoxidil may promote hair regrowth in patients experiencing persistent chemotherapy-induced alopecia, with trichoscopy aiding in treatment assessment.

In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

In an animal study with a skin defect model, this research reported that curcumin-loaded hydrogels made from recombinant humanized collagen and an eco-friendly crosslinker enhanced wound repair by promoting angiogenesis, granulation tissue formation, and hair follicle neogenesis, while providing antioxidant benefits.

This study found that PRP may increase hair density in breast cancer survivors with EIA or pCIA, but improvements did not differ statistically between treated and untreated sides.

This study suggests that permanent chemotherapy-induced alopecia can occur in pediatric patients with Ewing's sarcoma and that treatments like minoxidil could be beneficial, though may not lead to full hair regrowth.

This review discusses the common occurrence of docetaxel-induced hair loss in cancer patients, including permanent cases, and highlights current and experimental strategies like scalp cooling, minoxidil, and new clinical trials for managing and preventing this side effect.

This narrative focuses on the experiences of two women with permanent chemotherapy-induced alopecia, highlighting the severe psychological and social impact along with dissatisfaction over pre-treatment information about hair loss, which they initially believed to be temporary.

This study reports that mesenchymal stromal cell-derived extracellular vesicle injections led to complete hair regrowth in a patient with persistent chemotherapy-induced alopecia.

This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.

This report describes a case where a woman developed permanent alopecia after chemotherapy with taxanes for breast cancer, and she showed favorable response to 6 months of minoxidil topical treatment.

Age, diabetes, and cardiogenic shock at PCI are key factors linked to in-hospital death in STEMI patients with hypertension.

This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.

This study found significant racial and ethnic disparities in the incidence and psychological impact of chemotherapy-related alopecia, with Asian women experiencing the greatest burden, highlighting the need for personalized and culturally sensitive care.

This study suggests that pretreatment with a PPAR-γ modulator may prevent damage to hair follicle stem cells caused by a chemotherapy metabolite, potentially offering a strategy to mitigate permanent chemotherapy-induced alopecia.

Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.

This review highlights the challenges and management strategies associated with persistent chemotherapy-induced alopecia, detailing the psychosocial impacts, follicular pathobiology, and available treatments such as scalp cooling and minoxidil, ultimately proposing a clinical algorithm to transform it into a preventable and manageable condition.

This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.

This study highlights the need for targeted educational programs and better collaboration between dermatologists and oncologists to address knowledge gaps and improve patient care.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

Different cells affect hair follicle blood vessels, endothelial cells react differently to inflammation and oxidized fats, and prasugrel better protects heart vessels during a procedure than clopidogrel.